GHK-Cu / KPV Blend

Beauty Blend (GHK-Cu/KPV) – 50mg/20mg is a research-grade lyophilized peptide combination formulated for in vitro and preclinical laboratory investigations. Each vial contains 50 mg of GHK-Cu (copper tripeptide glycyl-L-histidyl-L-lysine copper complex) and 20 mg of KPV (alpha-MSH tripeptide Lys-Pro-Val), providing a dual-peptide substrate for exploring the intersecting biological pathways associated with tissue repair, inflammation resolution, and cellular homeostasis.

GHK-Cu: Copper Tripeptide Pharmacology

GHK-Cu (molecular formula C₁₄H₂₃N₆O₄Cu, MW ~340 Da) is a naturally occurring copper-binding tripeptide first isolated from human plasma by Loren Pickart in 1973. At physiological concentrations (approximately 200 ng/mL in young plasma, declining with age), GHK-Cu has been shown in preclinical research to modulate gene expression in a manner that promotes tissue remodeling and cellular repair.

Preclinical studies have investigated GHK-Cu's effects on:

- **Extracellular Matrix Remodeling:** In vitro experiments demonstrate that GHK-Cu upregulates collagen synthesis by fibroblasts while simultaneously stimulating matrix metalloproteinase (MMP) expression—MMPs that selectively degrade damaged collagen without affecting newly synthesized matrix. This bidirectional remodeling activity may explain the tripeptide's observed wound-healing properties in animal models.

- **Antioxidant Gene Expression:** Microarray analyses of GHK-Cu–treated human fibroblasts revealed upregulation of antioxidant defense genes including superoxide dismutase (SOD1, SOD2), catalase, and glutathione peroxidase. The copper complex appears to activate Nrf2 (nuclear factor erythroid 2–related factor 2), the master transcription factor of the antioxidant response element (ARE) pathway.

- **Angiogenesis Modulation:** GHK-Cu has been shown to stimulate VEGF (vascular endothelial growth factor) secretion in dermal fibroblasts under hypoxic conditions, potentially supporting new blood vessel formation during tissue repair in animal research models. Additionally, investigations into tube formation assays using HUVEC cells have reported pro-angiogenic activity at nanomolar concentrations.

- **Anti-Inflammatory Activity:** In LPS-stimulated macrophage cultures, GHK-Cu reduced pro-inflammatory cytokine secretion (TNF-α, IL-1β, IL-6) and downregulated NF-κB nuclear translocation. The mechanism is thought to involve copper-mediated modulation of reactive oxygen species (ROS) signaling upstream of inflammatory cascades.

- **Neurotrophin Modulation:** Some preclinical investigations report GHK-Cu–induced upregulation of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in neuronal cell cultures, suggesting potential relevance to neuroprotection research—though these findings remain preliminary and require further validation in established in vivo models.

- **Gene Expression Profiling:** A landmark study published by Pickart and Margolina (2018) identified GHK-Cu as a modulator of over 4,000 human genes—31.2% of genes relevant to cancer biology were upregulated to a more normal expression pattern, while 22.8% were downregulated. This broad genomic activity positions GHK-Cu as a compelling tool for transcriptomic research applications.

KPV: Alpha-MSH C-Terminal Tripeptide

KPV (Lys-Pro-Val, MW ~327 Da) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). Unlike full-length α-MSH (13 amino acids), KPV retains anti-inflammatory bioactivity while offering improved metabolic stability due to its small size, rendering it resistant to rapid proteolytic degradation.

Research into KPV's biological actions has focused on:

- **Melanocortin Receptor Interactions:** KPV binds melanocortin receptor subtypes (particularly MC1R and MC3R) expressed on immune cells including macrophages, monocytes, and dendritic cells. Receptor engagement triggers cAMP/PKA signaling that downregulates NFκB activation and suppresses pro-inflammatory mediator release.

- **Gastrointestinal Mucosal Research:** Notably, KPV has been investigated in rodent colitis models where intracolonic or oral administration reduced mucosal inflammation scores, preserved epithelial barrier integrity, and modulated the balance between pro-inflammatory (Th1/Th17) and regulatory T-cell populations. Research groups have explored oral delivery strategies exploiting KPV's small size and relative stability to gastric acid.

- **Skin and Dermal Research:** In cell culture experiments, KPV reduced keratinocyte production of IL-1β and IL-8 under inflammatory challenge conditions (UV exposure, cytokine stimulation), suggesting relevance for cutaneous inflammation models. Its MC1R agonism in melanocytes has also been studied in the context of pigmentation biology and melanogenesis regulation research.

- **Mast Cell Modulation:** KPV has demonstrated inhibitory effects on mast cell degranulation in preclinical models, reducing histamine release and tryptase secretion. This property is of particular interest to researchers studying IgE-mediated hypersensitivity and skin-barrier dysfunction.

- **Combination Synergy Hypothesis:** The co-formulation of GHK-Cu and KPV in a single research vial enables investigators to explore whether the two peptides act additively or synergistically. GHK-Cu's pro-remodeling and antioxidant properties may complement KPV's anti-inflammatory receptor-mediated activity, providing a broader research toolkit in a single preparation.

Formulation and Reconstitution

The lyophilized powder preserves peptide integrity during storage. For research use, the peptides are typically reconstituted separately or together in sterile bacteriostatic water (0.9% benzyl alcohol) or sterile saline, according to the experimental protocol:

- GHK-Cu component (50 mg): Soluble in aqueous media at concentrations up to 10 mg/mL; the copper complex imparts a characteristic blue-green color to solution. - KPV component (20 mg): Highly water-soluble; clear colorless solution.

When reconstituting the combined vial, researchers typically add diluent incrementally (e.g., 1–2 mL bacteriostatic water), allow gentle rotation to dissolve, then aliquot into per-experiment volumes. For cell culture work, 0.22 µm sterile filtration of the reconstituted solution is recommended before addition to culture media.

Storage Specifications

- Lyophilized (unopened): Stable at –20°C for up to 24 months; at 4°C for up to 6 months. - Reconstituted solution: Store at 4°C, use within 28 days; freeze aliquots at –80°C for extended storage. Avoid repeated freeze-thaw cycles. - Protect from light: Both peptides are sensitive to UV photodegradation. - Shipping: Typically shipped on dry ice or with cold packs; confirm cold-chain compliance upon receipt.

Analytical Specifications

- GHK-Cu (50 mg): Purity ≥98% by HPLC; identity confirmed by mass spectrometry (ESI-MS); copper content validated by ICP-MS. - KPV (20 mg): Purity ≥98% by HPLC; identity confirmed by LC-MS/MS. - Sterility: Manufactured under aseptic conditions; sterility testing per USP <71>. - Endotoxin: <1 EU/mg by LAL assay. - Certificate of Analysis provided with each vial documenting purity, identity, and batch-specific quality data.

Research Applications

The Beauty Blend formulation supports a range of basic and translational research questions:

1. **Skin biology and wound healing models** — fibroblast proliferation, collagen synthesis assays, scratch-wound migration studies. 2. **Inflammatory signaling in cell culture** — cytokine ELISA panels, NF-κB reporter assays, oxidative stress measurements in challenged keratinocytes or macrophages. 3. **Mucosal inflammation models** — ex vivo gut epithelial barrier studies, TEER measurements, cytokine profiling in intestinal organoids. 4. **Peptide pharmacokinetics** — stability testing in plasma, tissue distribution studies, metabolite identification. 5. **Combination peptide screening** — dose-matrix experiments exploring GHK-Cu × KPV interaction effects on target readouts. 6. **Transcriptomic and proteomic studies** — RNA-seq or proteomics experiments examining how each peptide individually or in combination alters gene expression landscapes in target cell types. 7. **Melanocortin pathway dissection** — receptor binding competition assays, downstream signaling studies (cAMP, MAPK, STAT pathways) using MC1R- or MC3R-expressing cell lines.

Scientific Context and Literature

The intersection of GHK-Cu and KPV biology lies at the junction of several active research fields: peptide therapeutics, dermatology, gastroenterology, and anti-aging biology. Key reference landmarks include:

- Pickart L, Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. *International Journal of Molecular Sciences*, 19(7), 1987. - Kannengiesser K, et al. (2008). Alpha-melanocyte stimulating hormone mediates macrophage migration inhibitory factor release from a monocyte/macrophage cell line. *Regulatory Peptides*, 151(1–3), 97–102. - Dalmasso G, et al. (2008). The peptide KPV mediates anti-inflammatory effects in a murine model of colitis. *Journal of Crohn's and Colitis*, 2(3), 195–205.

These references are provided for research context only and do not constitute endorsement of any therapeutic or clinical application.

Important Notice

This product is supplied strictly for research and laboratory use only. It has not been approved by the FDA or any regulatory authority for human or veterinary therapeutic use. It is not intended for diagnostic, prophylactic, or clinical purposes. Handling should be performed by qualified researchers in compliance with all applicable institutional biosafety protocols, local regulations, and ethical guidelines. This product must not be used in human subjects.